Papillary thyroid microcarcinoma should not be used as the basis for postoperative 131I therapy
Journal Title: Journal of Surgery : Concepts & Practice - Year 2023, Vol 28, Issue 6
Abstract
[Objective] To analyze the clinicopathological data of patients with papillary thyroid microcarcinoma (PTMC) and papillary thyroid non-microcarcinoma (non-PTMC) who received 131I therapy retrospectively, and compare the therapeutic response of the two groups of patients, so as to guide 131I therapy decisions for PTMC patients. [Methods] A total of 1 118 patients with papillary thyroid carcinoma (PTC) underwent 131I therapy in the Department of Nuclear Medicine, Tianjin Medical University General Hospital from January 2015 to December 2020 were enrolled. Chi-square test and Mann-Whitney U test were used to compare the differences of clinicopathological features and 131I therapy， therapeutic response between two groups. The incomplete response （IR）rate curves of the two groups were plotted by Kaplan-Meier analysis.[Results] The proportion of patients with multifocal, involvement of bilateral thyroid lobes in PTMC group were higher than those in non-PTMC group, and the proportion of patients with extra-thyroid extension, T4, N1b, stimulated thyroglobulin(sTg)>10 μg/L, and high risk stratified were lower than those in non-PTMC group (P<0.05). Most patients in PTMC group received remnant ablation for the first time, while more patients in non-PTMC group received adjuvant therapy and therapy for known disease (P<0.05). There was no statistically significant difference in 131I therapeutic response, the rates of excellent response(ER) and IR in two groups, and the differences in curves of IR rate between the two groups were also no statistically significance (P>0.05). [Conclusions] PTMC has a certain degree of invasiveness. As long as the patients were comprehensively evaluated and the standard 131I therapy was adopted, the treatment outcomes of patients with PTMC and non-PTMC were roughly the same. Therefore, the clinical value of the definition of PTMC is extremely limited in the formulation of 131I therapeutic dose regimens.
Authors and Affiliations
Xiaoyu CAI, Ruiguo ZHANG, Yujing HU, Renfei WANG, Yanzhu BIAN
Keywords
Related Articles
- EP ID EP750926
- DOI 10.16139/j.1007-9610.2023.06.08
- Views 20
- Downloads 1
Hotspots in basic and translational research of gastric cancer
The morbidity and mortality of gastric cancer are high, while the overall therapeutic effect is poor without satisfactory. Clinical obstacles, such as low early-diagnosis rate, tumor heterogeneity, lack of accurate class...
Size discrepancy between ultrasonic and pathological measurement of solitary cN0M0 papillary thyroid microcarcinoma
Objective To compare the size discrepancy between ultrasonic and pathological measurement of solitary cN0M0 papillary thyroid microcarcinoma (PTMC), and to explore their correlation with lymph node metastasis. Methods Fr...
The future directions of artificial intelligence in the biological benefit-dominated diagnosis and treatment of pancreatic cancer
Pancreatic cancer is a high malignant tumor with insidious onset, early metastasis, and extremely poor prognosis. How to improve the early diagnosis and the prognosis of the patients is the current research focus. Althou...
Systemic therapy alters the landscape of surgery in hepatocellular carcinoma： opportunities and challenges
Surgery is still the first choice for patients with hepatocellular carcinoma(HCC). However, about 70% of HCC patients in China are first diagnosed in the advanced stage and have lost the opportunity for surgery. Recently...
Application experience of enteroscopy ERCP in benign biliary stricture after cholecystojejunostomy
Benign biliary stricture is a common complication of cholecystojejunostomy and is hard to handle. Ente-roscopy ERCP possesses the advantages such as repeatability, minimally invasive, and compliance with normal physiolog...